Oncternal Therapeutics Statistics Share Statistics Oncternal Therapeutics has 2.96M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 2.96M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 14.22% Shares Floating 2.71M Failed to Deliver (FTD) Shares 1,650 FTD / Avg. Volume 2.65%
Short Selling Information The latest short interest is 138.62K, so 4.68% of the outstanding
shares have been sold short.
Short Interest 138.62K Short % of Shares Out 4.68% Short % of Float 4.86% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.8 and the forward
PE ratio is -0.09.
Oncternal Therapeutics's PEG ratio is
0.04.
PE Ratio -0.8 Forward PE -0.09 PS Ratio 40.15 Forward PS 1.6 PB Ratio 1.05 P/FCF Ratio -0.98 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Oncternal Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.94,
with a Debt / Equity ratio of 0.01.
Current Ratio 6.94 Quick Ratio 6.94 Debt / Equity 0.01 Debt / EBITDA 0.14 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $29.07K Profits Per Employee $-1.46M Employee Count 27 Asset Turnover 0.02 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -87.29% in the
last 52 weeks. The beta is 1.36, so Oncternal Therapeutics's
price volatility has been higher than the market average.
Beta 1.36 52-Week Price Change -87.29% 50-Day Moving Average 0.98 200-Day Moving Average 4.96 Relative Strength Index (RSI) 25.25 Average Volume (20 Days) 62,268
Income Statement In the last 12 months, Oncternal Therapeutics had revenue of 785K
and earned -39.48M
in profits. Earnings per share was -13.43.
Revenue 785K Gross Profit -28.97M Operating Income -41.71M Net Income -39.48M EBITDA 2.23M EBIT -39.48M Earnings Per Share (EPS) -13.43
Full Income Statement Balance Sheet The company has 6.7M in cash and 318K in
debt, giving a net cash position of 6.38M.
Cash & Cash Equivalents 6.7M Total Debt 318K Net Cash 6.38M Retained Earnings -197.78M Total Assets 15.6M Working Capital 8.99M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -32.16M
and capital expenditures 0, giving a free cash flow of -32.16M.
Operating Cash Flow -32.16M Capital Expenditures n/a Free Cash Flow -32.16M FCF Per Share -10.94
Full Cash Flow Statement Margins Gross margin is -3690.19%, with operating and profit margins of -5313.89% and -5029.17%.
Gross Margin -3690.19% Operating Margin -5313.89% Pretax Margin -5029.17% Profit Margin -5029.17% EBITDA Margin 284.71% EBIT Margin -5313.89% FCF Margin -4097.32%
Dividends & Yields ONCT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ONCT is $10,
which is 1786.8% higher than the current price. The consensus rating is "Hold".
Price Target $10 Price Target Difference 1786.8% Analyst Consensus Hold Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 8, 2024. It was a
backward
split with a ratio of 1:20.
Last Split Date Jan 8, 2024 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -30.51 Piotroski F-Score 2
